These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23522741)

  • 21. Unilateral facial angiofibromas--a segmental form of tuberous sclerosis.
    McGrae JD; Hashimoto K
    Br J Dermatol; 1996 Apr; 134(4):727-30. PubMed ID: 8733380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
    Tu J; Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful topical rapamycin treatment for facial angiofibromata in two children.
    Pynn EV; Collins J; Hunasehally PR; Hughes J
    Pediatr Dermatol; 2015; 32(3):e120-3. PubMed ID: 25790347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
    Mutizwa MM; Berk DR; Anadkat MJ
    Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
    [No Abstract]   [Full Text] [Related]  

  • 25. Laser treatment of angiofibromas in tuberous sclerosis.
    Pignatti M; Spaggiari A; Sala P; Loschi P; Fiumana E; Faggioli R
    Minerva Pediatr; 2014 Dec; 66(6):585-6. PubMed ID: 25336102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multiple and unilateral angiofibromas of the face: forme fruste of Bourneville tuberous sclerosis].
    García Muret MP; Pujol RM; de Moragas JM
    Ann Dermatol Venereol; 1998 May; 125(5):325-7. PubMed ID: 9747280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
    Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
    Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
    Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
    Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
    [No Abstract]   [Full Text] [Related]  

  • 29. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
    Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
    Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of angiofibromas with a scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up.
    Bittencourt RC; Huilgol SC; Seed PT; Calonje E; Markey AC; Barlow RJ
    J Am Acad Dermatol; 2001 Nov; 45(5):731-5. PubMed ID: 11606924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
    Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease].
    Bottyán K; Kemény L; Csoma ZR
    Orv Hetil; 2019 Mar; 160(13):516-520. PubMed ID: 30907099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
    Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
    Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the Index for Facial Angiofibromas: A new scoring tool to assess facial angiofibromas in the tuberous sclerosis complex.
    Dill PE; Bessis D; Guidi B; Hadj-Rabia S; Itin P; Koenig MK; Moreno-Artero E; Erlanger TE; Cattaneo M; Weber P; Wataya-Kaneda M
    J Am Acad Dermatol; 2022 Dec; 87(6):1448-1450. PubMed ID: 35940368
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
    Kaufman McNamara E; Curtis AR; Fleischer AB
    J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Laser Treatment for Angiofibromas in Tuberous Sclerosis.
    Gu Y; Verheyden MJ; Sebaratnam DF; Liu RC
    Dermatol Surg; 2024 Sep; 50(9):840-846. PubMed ID: 38728593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
    Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
    Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
    [No Abstract]   [Full Text] [Related]  

  • 39. Numerous fibrous papules of the face unassociated with any genodermatosis.
    Elifritz J; Krishnan RS; Donnelly H
    Dermatol Online J; 2007 Oct; 13(4):12. PubMed ID: 18319009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
    Hamada I; Yukutake Y; Morita Y; Ishikawa N; Shimizu K; Wataya-Kaneda M
    J Dermatol; 2024 Jun; 51(6):752-758. PubMed ID: 38619178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.